Part 3/8:
Initially, policymakers anticipated around 700,000 additional enrollees would join the program. Yet, the reality proved to be far more complex, as actual sign-ups surpassed expectations, resulting in a $2.7 billion overspend. This financial miscalculation has been exacerbated by drastic increases in pharmaceutical costs, which alone accounted for a $540 million rise in expenses.